Home    Back

Verdiperstat    (DrugBank: Verdiperstat)

2 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2
17Multiple system atrophy6

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 508 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04436510
(ClinicalTrials.gov)		July 28, 20201/6/2020HEALEY ALS Platform Trial - Regimen B VerdiperstatHEALEY ALS Platform Trial - Regimen B VerdiperstatAmyotrophic Lateral SclerosisDrug: Matching Placebo;Drug: VerdiperstatMerit E. Cudkowicz, MDBiohaven Pharmaceuticals, Inc.Enrolling by invitation18 YearsN/AAll160Phase 2;Phase 3United States
2NCT04297683
(ClinicalTrials.gov)		July 14, 20203/3/2020HEALEY ALS Platform Trial - Master ProtocolHEALEY ALS Platform TrialAmyotrophic Lateral SclerosisDrug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8Merit E. Cudkowicz, MDMassachusetts General HospitalRecruiting18 YearsN/AAll480Phase 2;Phase 3United States

17. Multiple system atrophy    [ 107 clinical trials,   153 drugs,   (DrugBank: 48 drugs),   59 drug target genes,   104 drug target pathways]
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 107 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04616456
(ClinicalTrials.gov)		December 202026/10/2020Effect of Verdiperstat on Microglial Activation in Well-characterized MSA PatientsEffect of Verdiperstat on Microglial Activation in Well-characterized MSA PatientsMultiple System Atrophy;Multiple System Atrophy, Cerebellar Variant;Multiple System Atrophy, Parkinson Variant (Disorder);Multiple System Atrophy (MSA) With Orthostatic HypotensionDrug: [F-18]PBR06;Drug: VerdiperstatBrigham and Women's HospitalBiohaven Pharmaceuticals, Inc.Not yet recruiting18 YearsN/AAll8Early Phase 1United States
2EUCTR2019-001100-38-DE
(EUCTR)		07/01/202007/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: BHV-3241
INN or Proposed INN: Verdiperstat		Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		422Phase 3United States;France;Austria;Germany;United Kingdom;Italy;China
3EUCTR2019-001100-38-AT
(EUCTR)		20/12/201929/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy (M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: BHV-3241
INN or Proposed INN: Verdiperstat		Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		422Phase 3United States;France;Austria;Germany;United Kingdom;Italy;China
4EUCTR2019-001100-38-FR
(EUCTR)		13/12/201903/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: BHV-3241
INN or Proposed INN: Verdiperstat		Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		252Phase 3United States;France;Austria;Germany;Italy;United Kingdom
5EUCTR2019-001100-38-GB
(EUCTR)		06/12/201911/10/2019A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple System Atrophy(M-STAR Study)Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study) Multiple System Atrophy
MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Name: BHV-3241
INN or Proposed INN: Verdiperstat		Biohaven Pharmaceuticals, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		422Phase 3United States;France;Austria;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT03952806
(ClinicalTrials.gov)		July 29, 201915/5/2019Study of BHV-3241 in Subjects With Multiple System AtrophyA Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)Multiple System AtrophyDrug: Verdiperstat;Drug: PlaceboBiohaven Pharmaceuticals, Inc.NULLActive, not recruiting40 Years80 YearsAll336Phase 3United States;Austria;France;Germany;Italy;United Kingdom

Back to top